Galecto Inc.
| NYSE: GLTO | Healthcare / Biotechnology / Denmark |
| 1.99 | +0.0100 | +0.51% | Vol 15.51K | 1Y Perf -10.00% |
| Mar 31st, 2023 15:59 DELAYED |
| BID | 1.85 | ASK | 2.08 | ||
| Open | 1.91 | Previous Close | 1.99 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 9.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 377.39 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 49.74 | Earnings Rating | — | |
| Market Cap | 51.09M | Earnings Date | 5th May 2023 | |
| Alpha | -0.09 | Standard Deviation | 0.17 | |
| Beta | 0.18 |
Today's Price Range 1.831.99 | 52W Range 1.042.95 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 10.56% | ||
| 1 Month | -9.55% | ||
| 3 Months | 73.04% | ||
| 6 Months | 5.29% | ||
| 1 Year | -10.00% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -60.26 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -55.96 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -60.19 | |||
Return on invested Capital Q | -17.52 | |||
Return on invested Capital Y | -36.49 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.70 | ||||
| 0.62 | ||||
| - | ||||
| - | ||||
| -1.40 | ||||
| -1.95 | ||||
| 0.62 | ||||
| 2.84 | ||||
| -22 947 600.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.90 | ||||
| 8.00 | ||||
| 0.01 | ||||
| 0.01 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.57 | -0.55 | 3.51 |
| Q03 2022 | -0.68 | -0.54 | 20.59 |
| Q02 2022 | -0.69 | -0.67 | 2.90 |
| Q01 2022 | - | -0.67 | - |
| Q04 2021 | -0.56 | -0.53 | 5.36 |
| Q03 2021 | -0.56 | -0.50 | 10.71 |
| Q02 2021 | -0.54 | -0.49 | 9.26 |
| Q01 2021 | -0.46 | -0.53 | -15.22 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th May 2023 |
| Estimated EPS Next Report | -0.56 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 15.51K |
| Shares Outstanding | 25.67K |
| Shares Float | 18.57M |
| Trades Count | 64 |
| Dollar Volume | 29.69K |
| Avg. Volume | 50.19K |
| Avg. Weekly Volume | 63.93K |
| Avg. Monthly Volume | 36.78K |
| Avg. Quarterly Volume | 49.87K |
Galecto Inc. (NYSE: GLTO) stock closed at 1.99 per share at the end of the most recent trading day (a 0.51% change compared to the prior day closing price) with a volume of 15.51K shares and market capitalization of 51.09M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Galecto Inc. CEO is Hans T. Schambye.
The one-year performance of Galecto Inc. stock is -10%, while year-to-date (YTD) performance is 73.04%. GLTO stock has a five-year performance of %. Its 52-week range is between 1.04 and 2.95, which gives GLTO stock a 52-week price range ratio of 49.74%
Galecto Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.62, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.96%, a ROC of -60.19% and a ROE of -60.26%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Galecto Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Galecto Inc.’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for Galecto Inc. is Strong Buy (1), with a target price of $9.5, which is +377.39% compared to the current price. The earnings rating for Galecto Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Galecto Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Galecto Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.39, ATR14 : 0.19, CCI20 : -0.87, Chaikin Money Flow : -0.27, MACD : -0.07, Money Flow Index : 54.28, ROC : 6.99, RSI : 49.41, STOCH (14,3) : 63.04, STOCH RSI : 1.00, UO : 44.27, Williams %R : -36.96), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Galecto Inc. in the last 12-months were:
Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis & impact a broad range of fibrotic & related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
CEO: Hans T. Schambye
Telephone: +45 70705210
Address: Ole Maaloes Vej 3, Copenhagen DK-2200, , DK
Number of employees: 20
